CAMP4 Therapeutics Corporation (CAMP) Stock

CAMP4 Therapeutics Corporation (CAMP) is a Healthcare stock trading at $4.11 (as of 2026-06-18), with a market capitalization of $227.95M and a trailing P/E of -1.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CAMP4 Therapeutics Corporation is a biotechnology company focused on discovering treatment options for patients. Founded in 2015 by Richard A. Young and Leonard Zon and headquartered in Cambridge, Massachusetts, it develops therapeutic candidates based on its discovery activities.

Valuation — source: SEC EDGAR (first-party)
Price$4.11
Market Cap$227.95M
P/E Ratio-1.8
EV / EBITDA-2.3
Price / Book7.04
Price / Sales55.30
DCF Value (model)$-7.63
DCF Upside vs Price-285.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.50M
Net Margin-2298.5%
Return on Equity-279.3%
Current Ratio6.15
Revenue Growth (YoY)436.5%
EPS Growth (YoY)-76.0%
FCF Growth (YoY)-35.2%
Financial Health — source: SEC EDGAR
Altman Z-Score-2.08 (distress)
Valuation vs Sector & Industry
Stock P/E-1.8
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-108.5%
vs Industry-110.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($42.38M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua Mandel-Brehm
Employees55
CountryUS
IPO Date2024-10-11

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Crescent Biopharma, Inc. (CBIO)
  • Neurogene Inc. (NGNE)
  • AC Immune S.A. (ACIU)
  • Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
  • Allogene Therapeutics, Inc. (ALLO)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Candel Therapeutics, Inc. (CADL)
CAMP earnings history · CAMP institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.